Parnax Lab schedules 44th AGM on Sep 29 for RPT approval

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • Parnax Lab holds 44th AGM on September 29, 2026
  • Shareholders approve related-party deals with Naxpar Pharma
  • Ladha Singhal & Associates appointed as statutory auditors
  • Remote e-voting open from September 26 to 28, 2026
powered bylight_fuzz_icon
50333333

*this image is generated using AI for illustrative purposes only.

Parnax Lab has scheduled its 44th Annual General Meeting for September 29, 2026. The meeting will address the adoption of FY26 accounts and key governance matters.

The event will be conducted through Video Conferencing or Other Audio-Visual Means, as permitted by Ministry of Corporate Affairs circulars. Shareholders holding shares as of the record date, September 22, 2026, are eligible to vote.

Ordinary Business Agenda

The ordinary business includes the reappointment of Mr. Mihir M. Shah as a director. He retires by rotation and offers himself for reappointment. Mr. Shah holds 1,141,250 shares in the company as of March 31, 2026.

Additionally, shareholders will vote to appoint M/s. Ladha Singhal & Associates as the statutory auditors. The firm will serve a five-year term from the conclusion of this AGM until the 49th AGM.

Related Party Transactions

A special business item involves approving material related-party transactions with Naxpar Pharma Private Limited, a subsidiary of Parnax Lab. The transactions cover sales and purchases of materials and interest received on loans.

Transaction Type Value Limit Duration
Sales of Materials ₹5 crore per transaction Oct 1, 2026 – Sep 30, 2027
Purchase of Materials ₹5 crore per transaction Oct 1, 2026 – Sep 30, 2027
Interest Received on Loan ₹1.5 crore aggregate Oct 1, 2026 – Sep 30, 2027

These arrangements are proposed for the financial years 2026-27 and 2027-28, valid until the next AGM in calendar year 2027. The Audit Committee has recommended these transactions, noting they are conducted at arm's length.

Voting Mechanism

Remote e-voting will be available from September 26, 2026, at 9:00 am to September 28, 2026, at 5:00 pm. The facility is provided by MUFG Intime India Private Limited. Shareholders can vote via NSDL, CDSL, or the InstaVote platform depending on their holding mode.

Historical Stock Returns for Parnax Lab

1 Day5 Days1 Month6 Months1 Year5 Years
-1.34%+3.57%0.0%0.0%0.0%0.0%

How might the approval of related-party transactions with Naxpar Pharma impact Parnax Lab's operational costs and profit margins in FY27?

What are the strategic implications of appointing Ladha Singhal & Associates for a five-year term regarding future audit consistency and regulatory compliance?

Could the reappointment of Mr. Mihir M. Shah signal any upcoming shifts in corporate governance or leadership strategy at Parnax Lab?

Parnax Lab approves revised directors report for FY26

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Board approved revised directors report for FY26
  • Secretarial audit report was also taken on record
  • Meeting held on August 26, 2026
  • Disclosure made under SEBI Regulation 30
powered bylight_fuzz_icon
49293205

*this image is generated using AI for illustrative purposes only.

Parnax Lab approved its revised directors report and secretarial audit report for FY26. The board meeting took place on August 26, 2026.

The directors considered these documents during a session that began at 3:30 pm and concluded at 4:00 pm. This disclosure follows an earlier outcome dated August 14, 2026.

Board Meeting Details

The board acted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that other details from the previous filing remain unchanged.

Preet Kukreja, Company Secretary and Compliance Officer, signed the disclosure.

Historical Stock Returns for Parnax Lab

1 Day5 Days1 Month6 Months1 Year5 Years
-1.34%+3.57%0.0%0.0%0.0%0.0%

What specific revisions were made to the directors' report compared to the initial filing on August 14, 2026, and do they signal any changes in strategic direction?

How might the approval of the secretarial audit report impact Parnax Lab's compliance standing with SEBI in the upcoming regulatory cycles?

Are there any pending shareholder resolutions or major corporate actions scheduled following this board meeting that could influence stock volatility?

More News on Parnax Lab

1 Year Returns:0.00%